Recombinant PD-L1 antibody (AA 19-238)
Quick Overview for Recombinant PD-L1 antibody (AA 19-238) (ABIN7453318)
Target
See all PD-L1 AntibodiesAntibody Type
Reactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- AA 19-238
-
Purpose
- Rabbit anti-PD-L1 Recombinant Monoclonal Antibody [BLR227K]
-
Immunogen
- residues 19-238 (ECD)
-
Isotype
- IgG
-
-
-
-
Application Notes
-
IP: 20 μL/1 mg lysate
WB: 01:01,00
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 100 μg/mL
-
Buffer
- Borate Buffered Saline (BBS) pH 8.2 with 0.1 % BSA and 0.09 % Sodium Azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C
-
Expiry Date
- 12 months
-
-
- PD-L1 (CD274 (PD-L1))
-
Alternative Name
- PD-L1
-
Background
- Background: PD-L1 is an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. PD-L1 is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma [taken from NCBI Entrez Gene (Gene ID: 55193)].
-
Gene ID
- 29126
-
NCBI Accession
- NP_054862
-
UniProt
- Q9NZQ7
-
Pathways
- Cancer Immune Checkpoints
Target
-